May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
Author Affiliations & Notes
  • J. J. Nassaralla, Jr.
    Instituto de Olhos de Goiania, Goiania, Brazil
    Retina and Vitreous,
  • B. R. A. Nassaralla, Jr.
    Instituto de Olhos de Goiania, Goiania, Brazil
    Cataract, Cornea and Refractive Surgery,
  • Footnotes
    Commercial Relationships  J.J. Nassaralla, None; B.R.A. Nassaralla, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 302. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. J. Nassaralla, Jr., B. R. A. Nassaralla, Jr.; Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):302. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal neovascularization secondary to age-related macular degeneration.

Methods: : We conducted a retrospective study of patients with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.

Results: : There were 500 patients with a mean age of 70.6 (± 11.8) years, and a mean visual acuity of 20/200 and a mean central foveal thickness of 356 (±221) microns. Most of the patients (42%) were failures by other means of treatment. At the one month follow-up the mean visual acuity improved to 20/125 (p<.001) and the mean central foveal thickness decreased to 238 (± 188) microns (p<0.002). And after 2 months follow-up the mean visual acuity improved to 20/100 (p<.001) and the mean central foveal thickness decreased to 213 (± 159) microns (p<0.001). Eight eyes who had a mild amount of intraocular inflammation, one patient had intraocular hemorrhage and one patient had infection following injection.

Conclusions: : Initial treatment results of patients with choroidal neovascularization secondary to age-related macular degeneration did not reveal any short-term safety concerns. Short-term results suggest that intravitreal bevacizumab (1.25 mg) is well tolerated and was associated with improvement in visual acuity, decreased retinal thickness by OCT, and reduction in angiographic leakage in most patients, The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Clinical Trial: : www.clinicaltrials.gov NCT00556348

Keywords: age-related macular degeneration • retinal neovascularization • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×